Safety and tolerability established over 52 weeks1

STIOLTO adverse event profile comparable to the individual components alone1

The 52-week adverse event profile of STIOLTO is comparable to those of SPIRIVA RESPIMAT (tiotropium bromide) Inhalation Spray and olodaterol.

STIOLTO RESPIMAT Adverse Reactions

STIOLTO had a lower discontinuation rate than either of its components1

The discontinuation rate due to adverse events was 7.4% compared to 9% for tiotropium and 9.9% for olodaterol.

Reference: 1. STIOLTO RESPIMAT [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2016.


STIOLTO RESPIMAT Inhalation Spray Packaging